Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Acino Holding AG's Enterprise Value is CHF0.00 Mil.
Acino Holding AG's EBIT for the trailing twelve months (TTM) ended in Dec. 2013 was CHF-18.33 Mil. Therefore, Acino Holding AG's EV-to-EBIT ratio for today is 0.00.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Acino Holding AG's Enterprise Value is CHF0.00 Mil.
Acino Holding AG's EBITDA for the trailing twelve months (TTM) ended in Dec. 2013 was CHF38.30 Mil. Therefore, Acino Holding AG's EV-to-EBITDA ratio for today is 0.00.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Acino Holding AG's Enterprise Value is CHF0.00 Mil.
Acino Holding AG's Revenue for the trailing twelve months (TTM) ended in Dec. 2013 was CHF321.15 Mil. Therefore, Acino Holding AG's EV-to-Revenue ratio for today is 0.00.
Acino Holding AG Enterprise Value Historical Data
The historical data trend for Acino Holding AG's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Acino Holding AG's Enterprise Value
For the Drug Manufacturers - General subindustry, Acino Holding AG's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Acino Holding AG's Enterprise Value Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Acino Holding AG's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Acino Holding AG's Enterprise Value falls into.
Acino Holding AG Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Acino Holding AG's Enterprise Value for the fiscal year that ended in Dec. 2013 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Acino Holding AG (LTS:0QM8) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Acino Holding AG's current Enterprise Value is CHF0.00 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Acino Holding AG's EBIT for the trailing twelve months (TTM) ended in Dec. 2013 was CHF-18.33 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Acino Holding AG's current Enterprise Value is CHF0.00 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Acino Holding AG's EBITDA for the trailing twelve months (TTM) ended in Dec. 2013 was CHF38.30 Mil.
Acino Holding AG's current Enterprise Value is CHF0.00 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Acino Holding AG's Revenue for the trailing twelve months (TTM) ended in Dec. 2013 was CHF321.15 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Acino Holding AG Enterprise Value Related Terms
Thank you for viewing the detailed overview of Acino Holding AG's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Acino Holding AG is a Switzerland-based company engaged in the pharmaceutical industry. The Company develops, manufactures, and markets pharmaceuticals in novel drug delivery forms internationally. It is divided into four segments Business to Consumer (BtC); Business to Business (BtB); Technology marketing (TM); and Production (Prod). The BtC segment comprises all direct marketing activities. Under the company's "Acino Switzerland" brand and, with the promise of Swiss quality, the company sells its products in emerging markets around the globe. This reporting segment includes the business purchased from Mepha/Cephalon in the Middle East, Africa, Latin America and Asia. The BtB segment comprises Acino's business with its internally developed products, for which the company also owns the intellectual property rights. Acino develops and produces high-quality medicines with proven active ingredients and modern drug delivery systems and grants licenses for them to leading pharmaceutical and generic pharmaceutical companies worldwide. The technology marketing segment comprises a broad spectrum of fully integrated contract services, including procurement, contract development, production and packaging for companies in the life sciences industry. On behalf of these customers, Acino develops a comprehensive product pipeline on the basis of its special technological know-how. This includes both new types of medicines as well as projects with innovative drug delivery systems for established active ingredients. The production segment is responsible for the manufacturing of products and the supplying of the other three segments, and generates turnover through the reimbursement of its services. The manufacturing costs of products are credited to the production segment at standard prices along with remuneration in the form of a mark-up for materials and production costs.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LTS:0QM8 has been successfully added to your 